Author
Listed:
- Hai Wang
(The Ohio State University
Comprehensive Cancer Center, The Ohio State University
Davis Heart and Lung Research Institute, The Ohio State University)
- Pranay Agarwal
(The Ohio State University
Davis Heart and Lung Research Institute, The Ohio State University)
- Shuting Zhao
(The Ohio State University
Davis Heart and Lung Research Institute, The Ohio State University)
- Jianhua Yu
(Comprehensive Cancer Center, The Ohio State University
The Ohio State University)
- Xiongbin Lu
(University of Texas MD Anderson Cancer Center)
- Xiaoming He
(The Ohio State University
Comprehensive Cancer Center, The Ohio State University
Davis Heart and Lung Research Institute, The Ohio State University)
Abstract
Nanoparticles have demonstrated great potential for enhancing drug delivery. However, the low drug encapsulation efficiency at high drug-to-nanoparticle feeding ratios and minimal drug loading content in nanoparticle at any feeding ratios are major hurdles to their widespread applications. Here we report a robust eukaryotic cell-like hybrid nanoplatform (EukaCell) for encapsulation of theranostic agents (doxorubicin and indocyanine green). The EukaCell consists of a phospholipid membrane, a cytoskeleton-like mesoporous silica matrix and a nucleus-like fullerene core. At high drug-to-nanoparticle feeding ratios (for example, 1:0.5), the encapsulation efficiency and loading content can be improved by 58 and 21 times, respectively, compared with conventional silica nanoparticles. Moreover, release of the encapsulated drug can be precisely controlled via dosing near infrared laser irradiation. Ultimately, the ultra-high (up to ∼87%) loading content renders augmented anticancer capacity both in vitro and in vivo. Our EukaCell is valuable for drug delivery to fight against cancer and potentially other diseases.
Suggested Citation
Hai Wang & Pranay Agarwal & Shuting Zhao & Jianhua Yu & Xiongbin Lu & Xiaoming He, 2015.
"A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents,"
Nature Communications, Nature, vol. 6(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms10081
DOI: 10.1038/ncomms10081
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms10081. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.